Collaborative Arrangement was Zymeworks’s largest revenue line in fiscal 2025, bringing in $338.00M of $404.30M (84%).
| Customer | FY 2025 |
|---|---|
| Collaborative Arrangement | $338.00M |
| Arrangement Other Than Collaborative | $66.30M |
| Total | $404.30M |
Zymeworks brought in $404.30M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. Collaborative Arrangement was the largest at $338.00M (83.6%), ahead of Arrangement Other Than Collaborative at $66.30M (16.4%).
License Agreement was Zymeworks’s largest revenue line in fiscal 2025, bringing in $338.00M of $344.00M (98%).
| Research And Development Arrangement Contract To Perform For Others By Type | FY 2025 |
|---|---|
| License Agreement | $338.00M |
| Platform Technology Transfer & License Agreement | $6.00M |
| Total | $344.00M |
Zymeworks brought in $344.00M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $404.30M it reports by customer, so these revenue lines do not cover all of its revenue. License Agreement was the largest at $338.00M (98.3%), ahead of Platform Technology Transfer & License Agreement at $6.00M (1.7%).
Milestone Revenue was Zymeworks’s largest product and service line in fiscal 2025, bringing in $20.00M of $38.30M (52%).
| Product and Service | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Drug Supply For Ongoing Studies | $25.66M | — | — | |
| Deferred Revenue | — | — | $18.30M | |
| Option Exercise Fee | — | $15.00M | — | |
| Milestone | — | — | — | |
| Other Drug Supply | $13.35M | $15.46M | — | |
| Upfront Fee | — | — | — | |
| Milestone Revenue | — | $2.50M | $20.00M | |
| Partner Revenue | — | — | — | |
| Research Support Payments & Other Service | $537.00K | $3.00M | — | |
| Royalties | — | $100.00K | — | |
| Total | $39.55M | $36.07M | $38.30M |
Zymeworks brought in $38.30M from its two product and service lines in fiscal 2025, the year ended May 31, 2025. Zymeworks regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $36.07M. Milestone Revenue was the largest at $20.00M (52.2%), ahead of Deferred Revenue at $18.30M (47.8%).
Zymeworks began breaking out Deferred Revenue in fiscal 2025 and Milestone Revenue in fiscal 2024. Zymeworks stopped reporting Drug Supply For Ongoing Studies ($25.66M in fiscal 2023), Other Drug Supply ($15.46M in fiscal 2024), Option Exercise Fee ($15.00M in fiscal 2024) and two others as separate lines.
Zymeworks (ZYME) reports its revenue by customer, by research and development arrangement contract to perform for others by type and by product and service. In fiscal 2025, Collaborative Arrangement was its largest revenue line, bringing in $338.00M (83.6% of the total), followed by Arrangement Other Than Collaborative at $66.30M (16.4%).
Collaborative Arrangement was Zymeworks' largest revenue line in fiscal 2025, bringing in $338.00M, or 83.6% of the $404.30M total across its two revenue lines.
Milestone Revenue was Zymeworks' largest product and service line in fiscal 2025, bringing in $20.00M, or 52.2% of the $38.30M total across its two product and service lines.
Every figure comes from Zymeworks' annual financial filings, as reported. Each line keeps the name Zymeworks gives it, and years follow its fiscal calendar.
Zymeworks' revenue by customer goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.